Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Vitamin D × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 18 Prostatic Neoplasms 10 Osteoporosis 7 Vitamin D Deficiency 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Polycystic Ovary Syndrome 5 Neoplasms 4 Obesity 3 Colonic Neoplasms 3 Carcinoma, Hepatocellular 3 Bone Diseases, Metabolic 3 Neoplasm Metastasis 2 Multiple Endocrine Neoplasia Type 1 2 Lymphoma 2 Lung Neoplasms 2 Leukemia 2 Leiomyoma 2 Inflammation 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Transitional Cell 2 Brain Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Solid Cancers 1 Rectal Neoplasms 1

Interventions

Cyclophosphamide 21 blinatumomab 16 Cytarabine 14 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 9 Blood Specimen Collection 8 Rituximab 7 Methotrexate 7 Dexamethasone 7 Daunorubicin 7 Lenalidomide 6 Vincristine 5 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Liquid Biopsy 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Doxorubicin 3 Cladribine 3 Chemotherapy, Adjuvant 3 Busulfan 3 Asparaginase 3 trastuzumab deruxtecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡